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Spheres of Influence
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It used to be that high technology meant
nuclear physics and missile systems, and
presented the threat of physical destruction.
Today, "high tech" means biotechnology and electronic communication systems, and the focus has shifted to con- 0
cerns about more subtle problems like ^
loss of privacy, inability to control personal information, and
the discriminations and other
adversities that often follow.
The Human Genome
Research Program is like a "big
bang" that created two expanding
universes: one full of galaxies of
biotechnological advances, the
other full of a myriad of laws dealing with the
handling and use of genetic information.
The legislative universe may be expanding at a greater rate. By recent count, 14
bills pertaining to the use
of genetic information
were introduced in the
104th Congress for consideration in 1996, and 7
bills are already on the agenda of the 105th
Congress. State legislatures, many of which
have enacted numerous laws over the last
decade to protect genetic information and
prevent discrimination, now face a surge of
over 60 bills to expand these protections, with
more being introduced each week-4 bills
will soon be introduced in Massachusetts, 5
bills have been introduced in both Hawaii
and Connecticut, and at least 11 bills are now
before legislators in Michigan. The focus of
these bills and prior laws is genetic privacy
and discrimination. These pieces of legislation
contain varying definitions of genetic testing
and genetic information; diverse rights and
duties for patients, doctors, employers, insurers, and other parties; and a variety of decision-making criteria, enforcement measures,
and sanctions.
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Why All the Fuss?
Since the advent of biotechnology, scientists
and biotech firms have touted genetic information as especially revealing, more so than
conventional medical information, of a person's current and future health status. The
public appears to accept that this revelatory
quality may pose new diagnostic and therapeutic opportunities and other health benefits, but also seems to perceive that such
information could expose individuals to a
broad range of informational abuses commonly encountered in society, from job and
insurance discrimination to manipulation
and constraints on personal choices and
freedoms. In addition, there is the prospect
that genetic information, much like psychiatric information, may provide new opportunities for hasty, arbitrary, and stigmatizing

labeling of individuals, without adequate
recourse for the victims of such labeling.
These concerns are reinforced by media
reports on the misuse of genetic information. Such accounts have included
announcements that a genetic basis for
certain behaviors, for example violence
and criminality, has been determined;
i that a patient's genetic information
h was sold by his physician to a compao ny that subsequently profited from the
information; that employers and insurers
seek and use genetic information to exclude
certain applicants in order to reduce financial risks and maximize profits; and that
adoption agencies, police, and other organizations want such information to make
decisions that will suit their agendas but
restrict individual choices, freedoms,
and opportunities.
Further reinforcing public
concerns about the vulnerabilities likely to be created by the
availability of more and more
genetic information is the failure
of numerous laws enacted over the years to
maintain the confidentiality of patient and
employee medical records. Privacy law can
be ambiguous and is open to broad interpretation by the courts. And special laws that
were enacted to aggressively prevent various
discriminations based on health status, such
as the Americans with Disabilities Act
(ADA), can be self-limiting. Despite 1995
guidance by the Equal Employment
Opportunity Commission that the ADA
protects those with "an inborn predisposition to a disease" as revealed by "genetic
information relating to illness, disease, or
other disorders" from discrimination in
employment, the EEOC guidance is advisory, lacks the force of law, and leaves resolution of individual cases to litigation and
court decisions.
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Finally, new health care policies and
electronic capabilities arouse public concerns about medical privacy, including
genetic privacy. Managed health care systems involve the compilation of information
on a patient from multiple physicians and
tests, and afford access to many parties,
including doctors, hospitals, clinics, pharmacists, state health agencies, administrators, insurers, employers, researchers, and
members of the patient's family. Protecting
medical and genetic information under
these circumstances is highly problematic
and is made more so by computerization
and electronic access.

The People's Rights
Various technological defenses are emerging
as possible means of ensuring medical and
genetic privacy. The New York Times, in an
editorial on 11 March 1997, called for
improved methods of protecting patient
records held by individual physicians or
health care providers, and for guarding such
information as it is transferred electronically
to employers, insurers, and others. In addition to strengthening the legal obligations of
various persons to protect patient information, the Times proposed that electronic
auditing of information access, dedicated
modem lines, and even encryption be used.
A similar approach was suggested recently by a special panel of the National
Research Council, which found that patient
records were inadequately protected in electronic systems. The panel called for technological safeguards, such as passwords and
"firewalls" (internal software impediments
to access) to prevent unauthorized access
and electronic auditing and to improve
information management. These approaches
are comparable to defenses being developed
to protect financial information and assure
privacy in new electronic investment and
banking systems on the Internet.
In a more traditional arena, many are
beginning to consider the courts incapable
of providing a coherent response to societal
concerns about genetic privacy and discrimination. Operating on a case-by-case basis
across the United States, courts must deal
with the specific factual and legal issues
unique to each case. Thus, they are called on
to construe diverse federal and state laws,
review specific administrative decisions, and
determine the constitutionality of narrow
statutory or regulatory requirements in a
variety of factual settings. Determinations
courts are being asked to make include, for
example, whether an insurance company or
employer should be obligated to reveal the
results of a genetic test it conducted on an
applicant or worker to a person, his or her
family, or others under the laws of a particu-

lar state. In another scenario, a court may be
asked to determine if an adoption agency,
workers' compensation insurer, spouse, or
other relative should have access to the
genetic information of individuals under
constitutional and common-law doctrines of
privacy and relevant federal and state
statutes. Judicial decisions on such matters
are case-specific and result in a bewildering
patchwork of rights and duties across the
United States.
Rarely does a clear national consensus
emerge from the determinations of hundreds of courts, although it is possible. For
example, relatively uniform decisions are
being reached by federal and state courts on
the constitutionality of state laws that
require the taking of genetic material (usually blood specimens for DNA) from convicted sexual offenders for inclusion in state
data banks for identification purposes.
Arguments that such a nonconsensual taking of genetic information is an unconstitutional search and seizure under the Fourth
Amendment of the United States
Constitution have failed because courts have
determined that the public interest in preventing recidivism and facilitating enforcement far outweighs the impairment of the
sexual offender's constitutional rights, and
that using DNA identifiers is comparable to
using fingerprints.
Given the array of concerns about the
misuse of genetic information, the new
health care policies and electronic communication systems that may compromise confidentiality, and the inability of the courts to
provide coherent solutions, privacy advocates
and other interest groups are calling for legislative solutions at state and federal levels.
State Laws
According to Wendy McGoodwin, executive director of the Council for Responsible
Genetics, a nonprofit bioethics advocacy
organization, a dual legislative strategy is
needed: laws to protect genetic privacy and
laws to prohibit genetically based discrimination. States are responding, especially to
the latter stratagem. At last count, 14 states
had enacted laws that address genetic testing
and discrimination by insurers, employers,
or both. California, Colorado, Georgia,
Maryland, Minnesota, New Hampshire,
Ohio, Oregon, Virginia, and Wisconsin
prohibit health insurers from rejecting applicants or changing their premiums on the
basis of genetic information. Iowa, New
Hampshire, New Jersey, New York,
Oregon, Rhode Island, and Wisconsin prohibit employers from requiring genetic tests
or using genetic health predictions in
employment decisions. In addition, many
other state legislatures have bills pending to
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protect individuals from these types of discriminatory activities.
The state laws vary in many ways. For
example, some forbid the use of genetic
information for nontherapeutic purposes or
for any underwriting or employment decision purposes, whereas others also prohibit
certain unauthorized disclosures. Some,
such as Maryland and Wisconsin, go further
and forbid insurers or employers from
requiring and requesting genetic testing.
The council's position paper on this
topic favors strong legislation to counter
genetic discrimination. McGoodwin disputes claims by insurers that genetic information is necessary to avoid ruinous economic losses. "Genetic conditions exist at a
fairly stable incidence in our society. There
is no epidemic," she said. "Thus, they are
already reflected in the actuarial tables used
by insurers to establish rates. In fact, insurers have always insured people at risk for
genetic conditions. The social goal of insurance is to spread the risk across communities. If genetic information is used to stigmatize individuals as substandard or uninsurable, the resulting stratification of the community into 'haves' and 'have nots' is contrary to the public interest."
The Biotechnology Industry Organization (BIO), based in Washington, DC, is
an international trade association of over
700 companies engaged in biotechnological
research and commerce that has been monitoring state legislative developments on
genetic information for its member companies. According to Suzanne Tomlinson,
bioethics counsel and outreach manager at
BIO, more than 60 bills on genetic privacy
and discrimination have been introduced in
state legislatures in 1997. Many are targeted
at preventing discrimination and unauthorized disclosures by employers and insurers
in those states that have not yet enacted
such measures, or expanding such protections in states that had previously enacted
narrowly protective statutes. Some of the
bills attempt to break new ground. A sizable
cluster (Texas, Vermont, Nebraska, New
Mexico, Michigan, Maryland, and Florida)
would provide individuals with a property
right to their genetic information, a development opposed by pharmaceutical and
biotech firms in New Jersey and elsewhere.
Several bills would amend existing privacy
and human rights laws to expressly encompass genetic information.

Federal Standards
This proliferation of diverse state laws obviously makes research, health care, and business more legally and economically problematic for biotech research firms and their customers. BIO, therefore, adopted a policy
489
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statement in late 1996 calling for "federal
standards to protect the confidentiality of an
individual's medical information, including
the results of genetic testing," emphasizing
that information from genetic testing "forms
part of the continuum of medical information," and should not be inappropriately
stigmatized. Federal standards to protect the
confidentiality of medical information
should, according to BIO, ensure that legitimate and vital medical research is facilitated
and should not impede the conduct of clinical trials or the reporting of results to agencies such as the Food and Drug
Administration, nor should they prevent the
use of "anonymized samples" in research.
BIO cites the Health Insurance
Portability and Accountability Act of 1996
(which it supported) as an example of an
appropriate federal law with uniform standards for preventing insurers from refusing
coverage or charging higher rates on the
basis of genetic history to persons enrolled
in group health insurance programs.
Following that example, BIO calls for a new
federal law that would set privacy standards
"national in scope to ensure legal uniformity
and consistency throughout the states, and
to avoid impeding medical research and
interstate commerce with a patchwork of
inconsistent laws."
BIO's proposal for federal standards that
would preempt inconsistent state laws
comes at a time when the federal legislative
agenda is quite crowded with bills of considerable complexity. Fourteen legislative proposals regarding genetic privacy and discrimination were introduced in the 104th
Congress; none were enacted. This year,
seven bills have already been introduced in
the 105th Congress and pressure grows for a
federal response.
The new federal bills differ in certain
respects. Several would amend the Social
Security Act and other major federal laws to
prevent group health plans and other health
insurers from using genetic information to
deny or cancel coverage or vary premiums,
and from requesting or requiring genetic
information or disclosing any such information without written authorization by the
person tested. One bill would also prohibit
employers from requesting genetic testing or
information from job applicants and
employees and using such information to
make discriminatory determinations. Several
of the bills provide for confidentiality of
such information but allow various exceptions in situations subject to criminal law or
court order, or where the information is
needed to establish paternity, identification
of a body, or diagnose a blood relative.
Patricia Roche, staff attorney of the
Health Law Department at the Boston
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University School of Public Health, points
to the problems of defining terms-including genetic information, genetic tests, and
genetic analysis-that face Congress.
Devising special procedures and duties for
genetic matters involves determining the
extent to which genetics is defined to be
part of an individual's private medical
records or treated separately. Congresswoman Harriette Chandler (DMassachusetts), chair of the state's health
care committee and co-chair of the special
committee on genetic information policy, is
drafting a bill to address this issue,
acknowledging its centrality and complexity. As part of this process, the Massachusetts
special committee is reviewing what other
states have done, paying particular attention
to the recent enactment of a New Jersey law
on the topic. New issues and situations continue to arise, says Chandler, such as the
case of so-called home brew test kits, which
are intended to enable a person to provide
samples (blood, urine, etc.) to laboratories
for analysis. Such laboratories promise confidentiality, so the question becomes how to
prevent access to the results of such tests by
employers, insurers, family members, and
even personal physicians.
A relatively comprehensive model bill for
federal enactment, covering virtually all concerns and issues, was drafted by Roche and
George Annas and Leonard Glantz, professors of health law at Boston University.
Their proposal for a Genetic Privacy Act was
followed closely by Senator Pete Domenici
(R-New Mexico) in drafting his 1996 federal
bill, the Genetic Confidentiality and
Nondiscrimination Act. Since no action was
taken on his 1996 bill, Domenici, along with
Senator Chris Dodd (D-Connecticut), introduced a revised version on 11 March 1997.
Although expected to attract considerable attention, the 1997 bill has been overshadowed thus far by another development:
Ian Wilmut's cloning of a sheep named
Dolly at the Roslin Institute near
Edinburgh, Scotland. Congressional hearings, featuring testimony by Wilmut, have
focused on this dramatic development, its
legal and ethical implications, and the
prospect of human cloning.
When the furor subsides, Congress will
face a number of proposals for legislation,
with the 1997 Domenici-Dodd bill being
the most notable because of its scope and
detail. This bill defines the circumstances
under which DNA samples and genetic
information may be collected, stored, analyzed, and disclosed, and establishes the
rights and responsibilities of the parties
involved. It also contains protections
against genetic discrimination in employment and insurance, and mechanisms to

enforce those proposed rights and responsibilities.
The most important features of the bill
are its attempts to establish national uniformity in genetic procedures, rights, and
duties amidst the chaos of state laws and
court decisions, and to balance individual
rights with other societal interests, including those of the genetics research and business communities. The bill relies on
informed consent procedures to assure privacy and control, prescriptive rules to prevent job and insurance discrimination, and
both federal enforcement and private laNvsuits to deter violations and ensure compliance.
The bill, which would become effective
1 January 1999 if enacted, cites findings
that existing legal protections for genetic
information are inadequate to ensure genetic
privacy and to prevent genetic discrimination, and that uniform rules will protect
individual privacy, prevent discrimination,
and encourage genetic research. It then
defines several terms, such as DNA, DNA
sample, genetic information, family,
research, insurer, and employer in order to
minimize ambiguities.
Title I of the bill establishes procedures
that make collection and genetic analysis of
a DNA sample contingent upon informing
the individual providing the sample about
the information likely to be derived, its
implications, and related matters, and upon
securing written authorization from the
individual. The individual's informed consent would also be required for any storage
or further use of the sample or access to it by
additional researchers.
Title II covers disclosure of genetic
information to third persons and makes any
such disclosure contingent upon "written
authorization of the individual" who is the
source of the DNA sample, except for compulsory disclosures required by any judicial,
legislative, administrative, or law enforcement proceeding. Authorized recipients are
forbidden to redisclose the information
without additional authorization by the
individual, except in cases involving "the
exercise of judgment for professional medical consultation for the direct benefit of a
patient." The individual is also authorized to
inspect clinical medical records that contain
genetic information derived from the sample
he or she provided, and is afforded the
opportunity to either have such records
amended or have a statement of disagreement included in the records.
Title III specifies the content of written
authorization for collecting, storing, and
analyzing DNA samples and for disclosing
and redisclosing genetic information to
third parties. It also provides that the indi-
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vidual may consent to subsequent use of the
DNA sample for research, future use without identifiers and "commercial use of the
DNA sample, with a waiver of, or provision
for, economic benefit to the individual."
Title IV deals with job and insurance
discrimination. It forbids employers from
requesting, requiring, or using the genetic
information of an employee or job applicant for the purpose of restricting any right
or benefit otherwise due or available to such
person. Exception is made "for the purpose
of permitting a genetically susceptible
employee to avoid occupational exposure"
to mutagens or teratogens, or for "determining a genotype that is otherwise directly
related to the work and is consistent with
business necessity." It also prohibits virtually any discriminatory actions against an
individual or family member by an insurer
offering a health insurance policy.
Title V establishes a protocol for
research involving genetic analysis that
includes safeguards against disclosure of
genetic information, assurance that necessary authorizations will be secured, destruction of DNA samples unless retention has
been authorized, and various other protections against misuse of genetic samples and
information. However, records may be
inspected "for the purpose of compiling data
for statistical or epidemiological studies" if
personal identifiers are not copied, removed,
or redisclosed. Title VI further amplifies the
protocol with regard to transfer or discontinuance of control of DNA samples and
genetic information.
Title VII deals with enforcement. It
authorizes any individual whose rights have
been violated under the act to bring a civil
action for damages of up to $50,000 or
injunctive relief in federal or state courts. In
addition, at the discretion of the Attorney
General, a violator may be prosecuted and
subject to restraining orders and injunctions, a $50,000 civil penalty, and the investigation and litigation costs incurred by the
government.
Title VIII prohibits any state law, regulation, or court decision on many of the
subjects covered by the bill unless it either
"more completely protects the confidentiality or privacy of an individual with respect to
genetic information about the individual"
than does the bill, or else affords the individual a greater right of access to his or her
genetic information. Strict state conformance to the limitations on disclosure set
forth in the bill is required. And individuals
are expressly allowed to pursue any other
remedies under common or statutory law
regarding collection, storage, or analysis of
DNA samples, and the disclosure of genetic
frm

Reactions to the bill are mixed but tend
to be favorable. According to Annas, "The
bill is a big step in the right direction, but
the DNA should be made the property of
the individual from whom it is taken. This
would be a more direct and understandable
legal concept than the bill's reliance on
informed consent procedures to protect
privacy and prevent discrimination.
McGoodwin, however, finds the bill's
reliance on informed consent procedures
acceptable, saying, "A property right to
one's DNA is not essential for protecting
privacy and preventing discrimination."
Annas also supports the bill's focus on
genetic privacy rather than medical privacy
in general. "There should be national standards for medical privacy but genetic privacy deserves the special attention accorded to
it by this bill because of its special quality,
namely that it is the 'future diary' of one's
predisposition to disease."
The major deficiency of the bill, according to Annas, is that it does not do enough
to protect the privacy of the very young. He
says, "Testing children and fetuses for predisposition to disease may be justified if there is
a legitimate basis for parental concern, such
as where there is family history of genetic
disease [that] is treatable before majority.
Otherwise, genetic testing before majority
could lead to special parental constraints on
the child's development, essentially stigmatize the child within the family, and have
other hurtful consequences. This is a difficult
issue and more guidance is needed."
McGoodwin finds the bill's definition of
"DNA sample" in terms of human tissue, to
the exclusion of blood and other sources of
DNA, acceptable, she says, because she
believes "human tissue" will be broadly construed to include these other sources.
However, she finds the bill's definition of
genetic information "woefully inadequate,
much too narrow, and leaving many vulnerable [people] without adequate protection."
The 1997 bill, she says, "addresses genetic
information from DNA analysis only, and
ignores other sources of genetic information
such as medical examinations and family
medical history. We need to define genetic
information more broadly as information on
inherited characteristics. Otherwise, family
members will not be afforded protection
against discrimination by this bill."
McGoodwin and Annas also want clarification of the legal effect of the DomeniciDodd bill on state law. Both find Title VIII
to be equivocal in calling for "more protective" state law but with the exception that
state laws strictly conform to the bill's provisions on matters involving disclosure. The
latter provision, in their view, could deter
states from trying to be more protective.
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Another perspective on the DomeniciDodd bill has been taken by the
Pharmaceutical Research and Manufacturers
of American (PhRMA). According to Gary
Persinger, the trade association's vice president for research and information services,
pharmaceutical firms are concerned about the
impacts on research of the bill, should it
become law. Says Persinger, "In dealing
expansively with privacy and discrimination
issues, the bill could inadvertantly obstruct
research that benefits health care throughout
society."
Persinger points to Title V, which sets
forth new legal requirements for
Institutional Review Board approval of clinical research on DNA samples in which the
board must find that the potential benefit to
society of the research outweighs individual
risks, including psychosocial risks. "What
are 'psychosocial risks'?" Persinger asks.
"Nowhere in this bill is this term defined,
and this term will be subject to various
interpretations by different [boards].
PhRMA prefers that such requirements be
set by the National Bioethics Advisory
Commission and NIH, not by congressional
action, to avoid risks of misinterpretation."
Similarly, PhRMA members want assurance that patient-identifiable information
will not be given an unreasonably broad definition that could unduly impede research,
and clarification that the multiple informed
consent procedures set forth in the bill can
be satisfied by a single written instrument.
Among the group's other concerns are
the bill's "conditional" approach to state law
preemption, and its separation of genetic
information from medical information,
which "could lead to problems," Persinger
said, "because genetic information may
become an integral part of medical records
and conflicts could arise over information
which could be regarded as being both medical and genetic."
The Domenici-Dodd bill now awaits
congressional deliberation. Domenici has
expressed the hope that the bill will "invite
exhaustive debate and legislative review, so
that we will achieve a firm national standard
on genetic privacy." But all affected parties
will have to reckon with a multitude of new
rules and procedures should the bill become
law, and its provisions will be tested by litigation and construed by courts over time.
So a firm national standard may not be
readily achievable in a legal universe beset by
pressures to make genetic information
"nobody else's business" and countervailing
pressures to disclose and use the information
for medical and economic advantage.

Michael Baram
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